Intravenous Immunoglobulin (IVIG) in Lung Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2010

Conditions
HypogammaglobulinemiaLung Transplantation
Interventions
DRUG

IVIG

10% Caprylate/Chromatography Purified Intravenous Immunoglobulin 400 mg/kg IV every 4 weeks

OTHER

Placebo

0.1% Albumin in an equal volume to the investigational product

Trial Locations (1)

10032

New York Presbyterian Hospital Lung Transplant Program, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Grifols Therapeutics LLC

INDUSTRY

lead

Columbia University

OTHER

NCT00115778 - Intravenous Immunoglobulin (IVIG) in Lung Transplantation | Biotech Hunter | Biotech Hunter